Files and links (2)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
MMWR. Recommendations and reports, v 72(3), pp 1-39
08 Sep 2023
PMID: 37669242
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This report compiles and summarizes all published recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. This report also includes updated and new clinical guidance for implementation from CDC Before 2021, ACIP recommended 23-valent pneumococcal polysaccharide vaccine (PPSV23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in combination with 1–3 doses of PPSV23 in series (PCV13 followed by PPSV23), for use in U.S. adults depending on age and underlying risk for pneumococcal disease. In 2021, two new pneumococcal conjugate vaccines (PCVs), a 15-valent and a 20-valent PCV (PCV15 and PCV20), were licensed for use in U.S. adults aged ≥18 years by the Food and Drug Administration ACIP recommendations specify the use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥65 years and for adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not received a PCV or whose vaccination history is unknown. In addition, ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23 Updated and new clinical guidance for implementation from CDC includes the recommendation for use of PCV15 or PCV20 for adults who have received PPSV23 but have not received any PCV dose. The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only and adults who are hematopoietic stem cell transplant recipients
Metrics
Details
- Title
- Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
- Creators
- Miwako Kobayashi - Centers for Disease Control and PreventionTamara Pilishvili - Centers for Disease Control and PreventionJennifer L Farrar - Centers for Disease Control and PreventionAndrew J Leidner - Centers for Disease Control and PreventionRyan Gierke - Centers for Disease Control and PreventionNamrata Prasad - Centers for Disease Control and PreventionPedro Moro - Centers for Disease Control and PreventionDoug Campos-Outcalt - University of ArizonaRebecca L Morgan - McMaster UniversitySarah S Long - Drexel UniversityKatherine A Poehling - Wake Forest UniversityAdam L Cohen - Centers for Disease Control and Prevention
- Publication Details
- MMWR. Recommendations and reports, v 72(3), pp 1-39
- Publisher
- Centers Disease Control & Prevention
- Number of pages
- 40
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:001154194900001
- Scopus ID
- 2-s2.0-85169767031
- Other Identifier
- 991021157211704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
Highly Cited Paper
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Public, Environmental & Occupational Health